PRODUCT

Semaglutide (5 mg Vial)

No short description available.

Quickstart Highlights

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with a prolonged half-life of approximately 7 days[1], approved for chronic weight management and glycemic control. The extended half-life enables once-weekly subcutaneous dosing, which is the standard clinical approach[1]. This educational protocol presents a gradual weekly titration from 0.25 mg up to a maintenance dose of 2.4 mg over 16+ weeks, using a practical dilution for precise insulin-syringe measurements.

Reconstitute: Add 2.0 mL bacteriostatic water → ~2.5 mg/mL concentration.
Weekly dose range: 250–2400 mcg (0.25–2.4 mg) once weekly (gradual escalation protocol).
Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL ≈ 25 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 28 days.

Molecular Info

Chain Length:31 amino acids
Sequence Type:GLP-1 receptor agonist
Molecular Weight:4,113.64 Da
Amino Acid Sequence:His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Modification:Acylated with C18 fatty diacid via γ-Glu spacer for extended half-life

Research Indications

Weight Loss

moderate

FDA-Approved Weight Management
Approved as Wegovy for chronic weight management with average 15-20% body weight reduction
Sustained Appetite Control
Reduces hunger and increases satiety through central GLP-1 receptor activation
Long-Term Weight Maintenance
Clinical trials show sustained weight loss over 2+ years with continued treatment

Diabetes

effective

Comprehensive Glucose Control
FDA-approved for type 2 diabetes with HbA1c reductions of 1.5-2% and low hypoglycemia risk
Cardiovascular Benefits
Proven reduction in major cardiovascular events in high-risk diabetes patients
Flexible Treatment Options
Available as weekly injection (Ozempic) or daily oral tablet (Rybelsus)

Metabolic

effective

Metabolic Health Improvement
Addresses multiple metabolic parameters including weight, glucose, blood pressure, and lipids
Anti-Inflammatory Effects
Reduces systemic inflammation markers beyond weight loss effects
Liver Health Benefits
Emerging evidence for improvements in non-alcoholic fatty liver disease

Reconstitution

Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall to minimize foaming; avoid shaking.
Gently swirl or roll the vial until the powder is fully dissolved.
Label the vial with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.
Label the vial with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Interactions

Insulin

Monitor Combination

May increase risk of hypoglycemia when combined with insulin; requires blood glucose monitoring and potential insulin dose adjustment

Tirzepatide

Avoid Combination

Both are incretin mimetics with overlapping mechanisms; concurrent use increases side effects without additional benefit

Cagrilintide

Synergistic

Combined as CagriSema in clinical trials - amylin analog (cagrilintide) + GLP-1 agonist (semaglutide) for enhanced weight loss

Metformin

Compatible

Commonly used together for diabetes management; complementary mechanisms with good safety profile

Growth Hormone Peptides

Compatible

No known interactions; different mechanisms of action and receptor targets

BPC-157

Compatible

No contraindications; BPC-157 may help with GI side effects if they occur

Sulfonylureas

Monitor Combination

Increased hypoglycemia risk; may require sulfonylurea dose reduction when initiating semaglutide

Oral Medications

Requires Timing

Delayed gastric emptying may affect absorption of oral medications; consider timing adjustments

Protocol Overview

Goal:Support chronic weight management through GLP-1 receptor activation, leading to reduced appetite and improved metabolic parameters[1].
Schedule:Weekly subcutaneous injections for 16–20+ weeks with gradual dose escalation.
Dose Range:250 mcg (0.25 mg) to 2400 mcg (2.4 mg) weekly with stepwise titration every 4 weeks to improve tolerability.
Reconstitution:2.0 mL per 5 mg vial (~2.5 mg/mL) for accurate unit measurements on standard insulin syringes.
Storage:Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 28 days; avoid repeated freeze–thaw cycles.

Dosage Protocols

Weeks 1–4:250 mcg (0.25 mg) once weekly to establish baseline tolerance.
Weeks 5–8:500 mcg (0.5 mg) once weekly.
Weeks 9–12:1000 mcg (1.0 mg) once weekly.
Weeks 13–16:1700 mcg (1.7 mg) once weekly.
Weeks 17+ (Maintenance):2400 mcg (2.4 mg) once weekly as target maintenance dose.
Frequency:Once per week (subcutaneous injection).
Timing:Administer on the same day each week at any time; rotate injection sites to reduce local irritation.

Dosage Protocols

Weight Loss Initiation:0.25mgWeekly x 4 weeks, then increase
Weight Loss Maintenance:2.4mgWeekly (after 16-week titration)
Diabetes Management:0.5-1mgWeekly
Cardiovascular Protection:0.5-1mgWeekly
Tolerability-Based:0.25-2.4mgWeekly (individualized)

Route:injectable

Storage Instructions

Lyophilized:Proper storage preserves peptide quality and efficacy[7][8]. Lyophilized (powder): Store at −20 °C (−4 °F) in a cool, dry place protected from light. For short-term storage (under a few months), 2–8 °C (35.6–46.4 °F) refrigeration is acceptable[7]. Avoid humidity to prevent peptide degradation. Reconstituted (solution): Refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze[8]. Use within 28 days for maximum potency and safety; the benzyl alcohol in bacteriostatic water inhibits bacterial growth but solutions should still be discarded after approximately 4 weeks[9]. Allow vials to reach room temperature before opening to minimize condensation uptake.
Reconstituted:Proper storage preserves peptide quality and efficacy[7][8]. Lyophilized (powder): Store at −20 °C (−4 °F) in a cool, dry place protected from light. For short-term storage (under a few months), 2–8 °C (35.6–46.4 °F) refrigeration is acceptable[7]. Avoid humidity to prevent peptide degradation. Reconstituted (solution): Refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze[8]. Use within 28 days for maximum potency and safety; the benzyl alcohol in bacteriostatic water inhibits bacterial growth but solutions should still be discarded after approximately 4 weeks[9]. Allow vials to reach room temperature before opening to minimize condensation uptake.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each injection; dispose in a proper sharps container[11].
Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and avoid lipohypertrophy[10].
Inject slowly and steadily; wait a few seconds before withdrawing the needle to ensure complete delivery.
Administer on the same day each week for consistency; if a dose is missed, take it as soon as possible within 5 days of the missed dose[4].
GLP-1 receptor agonists may cause gastrointestinal side effects (nausea, vomiting); gradual dose escalation helps minimize these effects[1][3].
The 5 mg vial size offers flexible dosing options—plan for 1 vial per 8 weeks during the initial escalation phase.

Reconstitution

If using pre-filled pen, attach new needle and prime according to instructions
If using vial, draw prescribed dose with appropriate syringe
Clean injection site with alcohol swab and let dry
Inject subcutaneously at 90-degree angle (45-degree if lean)
Hold for 6 seconds after injection to ensure full dose delivery
Dispose of needle safely and rotate injection sites weekly

Route:injectable

How It Works

Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1[4]. It promotes weight loss through multiple mechanisms: reducing appetite and food intake via central nervous system effects, slowing gastric emptying, and improving glycemic control through glucose-dependent insulin secretion[1][3]. The extended half-life of approximately 7 days is due to albumin binding and resistance to DPP-4 degradation, enabling convenient once-weekly dosing[1]. Clinical trials have demonstrated significant weight loss (mean 10–15% body weight reduction) in individuals with obesity when combined with lifestyle interventions[1][5]. The weekly 2.4 mg maintenance dose is FDA-approved for chronic weight management and represents the standard clinical approach[3][4].

Lifestyle Factors

Maintain a balanced, calorie-controlled diet with adequate protein intake (1.2–1.6 g/kg body weight) to preserve lean muscle mass during weight loss.
Combine regular physical activity including both resistance training (2–3 days per week) and aerobic exercise (150+ minutes per week) to reinforce metabolic adaptations and improve body composition.
Prioritize consistent sleep (7–9 hours nightly) and effective stress management to support adherence and metabolic health.
Stay well-hydrated (8–10 glasses of water daily), especially if experiencing gastrointestinal side effects.
Monitor progress through regular weigh-ins, body measurements, photos, and consultation with healthcare providers.
Consider working with a registered dietitian for personalized nutrition guidance during weight loss.

Injection Technique

Clean the vial stopper and chosen skin site with separate alcohol swabs; allow both to dry completely before proceeding[11].
Pinch a fold of skin between your fingers; insert the needle at a 45–90° angle into the subcutaneous tissue (fatty layer, not muscle)[10][12].
Do not aspirate (pull back the plunger) when giving a subcutaneous injection[10].
Inject the solution slowly and steadily; wait at least 6 seconds after injection before withdrawing the needle to ensure complete delivery and minimize leakage.
Withdraw the needle and apply light pressure with a clean swab; avoid rubbing vigorously.
Rotate injection sites systematically (abdomen, thighs, upper arms) with each weekly injection to prevent lipohypertrophy and maintain consistent absorption[11]. The abdomen is the preferred site for most consistent absorption.
Dispose of used syringes and needles immediately in a proper FDA-approved sharps container[12].

Benefits and Side Effects

Benefits

Observations from clinical literature and regulatory approvals[1][3][5].

Semaglutide (5 mg Vial)

Resources

Categories

Company